ADENOSINE injection solution

Maa: Yhdysvallat

Kieli: englanti

Lähde: NLM (National Library of Medicine)

Aktiivinen ainesosa:

ADENOSINE (UNII: K72T3FS567) (ADENOSINE - UNII:K72T3FS567)

Saatavilla:

Baxter Healthcare Corporation

INN (Kansainvälinen yleisnimi):

ADENOSINE

Koostumus:

ADENOSINE 3 mg in 1 mL

Prescription tyyppi:

PRESCRIPTION DRUG

Valtuutuksen tilan:

Abbreviated New Drug Application

Valmisteyhteenveto

ADENOSINE- ADENOSINE INJECTION, SOLUTION
BAXTER HEALTHCARE CORPORATION
----------
ADENOSINE INJECTION
FOR RAPID BOLUS INTRAVENOUS USE
RX ONLY
DESCRIPTION
Adenosine is an endogenous nucleoside occurring in all cells of the
body. It is chemically 6-amino-9-
ß-D-ribofuranosyl-9-H-purine and has the following structural
formula:
C
H N O
267.24
Adenosine is a white crystalline powder. It is soluble in water and
practically insoluble in alcohol.
Solubility increases by warming and lowering the pH. Adenosine is not
chemically related to other
antiarrhythmic drugs. Adenosine injection is a sterile, nonpyrogenic
solution for rapid bolus intravenous
injection. Each mL contains 3 mg adenosine and 9 mg sodium chloride in
Water for Injection. The pH of
the solution is between 4.5 and 7.5.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Adenosine slows conduction time through the A-V node, can interrupt
the reentry pathways through the
A-V node, and can restore normal sinus rhythm in patients with
paroxysmal supraventricular tachycardia
(PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
Adenosine is antagonized competitively by methylxanthines such as
caffeine and theophylline, and
potentiated by blockers of nucleoside transport such as dipyridamole.
Adenosine is not blocked by
atropine.
HEMODYNAMICS
The intravenous bolus dose of 6 or 12 mg adenosine usually has no
systemic hemodynamic effects.
When larger doses are given by infusion, adenosine decreases blood
pressure by decreasing peripheral
resistance.
PHARMACOKINETICS
Intravenously administered adenosine is rapidly cleared from the
circulation via cellular uptake,
primarily by erythrocytes and vascular endothelial cells. This process
involves a specific
transmembrane nucleoside carrier system that is reversible,
nonconcentrative, and bidirectionally
symmetrical. Intracellular adenosine is rapidly metabolized either via
phosphorylation to adenosine
monophosphate by adenosine kinase, or via deamination to inosine by
adenosine deaminase in the
cytosol. Since ad